ArticleTrials2018

A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.

Jemal Hussein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.